309 related articles for article (PubMed ID: 37969416)
1. Systemic treatment for advanced pancreatic cancer.
Leowattana W; Leowattana P; Leowattana T
World J Gastrointest Oncol; 2023 Oct; 15(10):1691-1705. PubMed ID: 37969416
[TBL] [Abstract][Full Text] [Related]
2. Advances in Targeted Therapy and Immunotherapy for Pancreatic Cancer.
Liu X; Li Z; Wang Y
Adv Biol (Weinh); 2021 Mar; 5(3):e1900236. PubMed ID: 33729700
[TBL] [Abstract][Full Text] [Related]
3. Pancreatic cancer: from state-of-the-art treatments to promising novel therapies.
Garrido-Laguna I; Hidalgo M
Nat Rev Clin Oncol; 2015 Jun; 12(6):319-34. PubMed ID: 25824606
[TBL] [Abstract][Full Text] [Related]
4. Immunotherapy for pancreatic cancer.
Kotteas E; Saif MW; Syrigos K
J Cancer Res Clin Oncol; 2016 Aug; 142(8):1795-805. PubMed ID: 26843405
[TBL] [Abstract][Full Text] [Related]
5. Opportunities and challenges in targeted therapy and immunotherapy for pancreatic cancer.
Cao D; Song Q; Li J; Jiang Y; Wang Z; Lu S
Expert Rev Mol Med; 2021 Dec; 23():e21. PubMed ID: 34906271
[TBL] [Abstract][Full Text] [Related]
6. Current status of biomarker and targeted nanoparticle development: The precision oncology approach for pancreatic cancer therapy.
Zhu L; Staley C; Kooby D; El-Rays B; Mao H; Yang L
Cancer Lett; 2017 Mar; 388():139-148. PubMed ID: 27916607
[TBL] [Abstract][Full Text] [Related]
7. The State-of-the-Art of Phase II/III Clinical Trials for Targeted Pancreatic Cancer Therapies.
Garcia-Sampedro A; Gaggia G; Ney A; Mahamed I; Acedo P
J Clin Med; 2021 Feb; 10(4):. PubMed ID: 33546207
[TBL] [Abstract][Full Text] [Related]
8. Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015.
Ascierto PA; Agarwala S; Botti G; Cesano A; Ciliberto G; Davies MA; Demaria S; Dummer R; Eggermont AM; Ferrone S; Fu YX; Gajewski TF; Garbe C; Huber V; Khleif S; Krauthammer M; Lo RS; Masucci G; Palmieri G; Postow M; Puzanov I; Silk A; Spranger S; Stroncek DF; Tarhini A; Taube JM; Testori A; Wang E; Wargo JA; Yee C; Zarour H; Zitvogel L; Fox BA; Mozzillo N; Marincola FM; Thurin M
J Transl Med; 2016 Nov; 14(1):313. PubMed ID: 27846884
[TBL] [Abstract][Full Text] [Related]
9. TMEM92 acts as an immune-resistance and prognostic marker in pancreatic cancer from the perspective of predictive, preventive, and personalized medicine.
Zhang S; Wan X; Lv M; Li C; Chu Q; Wang G
EPMA J; 2022 Sep; 13(3):519-534. PubMed ID: 36061829
[TBL] [Abstract][Full Text] [Related]
10. Perspectives in the treatment of pancreatic adenocarcinoma.
Cid-Arregui A; Juarez V
World J Gastroenterol; 2015 Aug; 21(31):9297-316. PubMed ID: 26309356
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapeutic Approaches to Biliary Cancer.
Shah UA; Nandikolla AG; Rajdev L
Curr Treat Options Oncol; 2017 Jul; 18(7):44. PubMed ID: 28660602
[TBL] [Abstract][Full Text] [Related]
12. Chemotherapy for pancreatic cancer.
Springfeld C; Jäger D; Büchler MW; Strobel O; Hackert T; Palmer DH; Neoptolemos JP
Presse Med; 2019 Mar; 48(3 Pt 2):e159-e174. PubMed ID: 30879894
[TBL] [Abstract][Full Text] [Related]
13. Current immunotherapeutic approaches in pancreatic cancer.
Koido S; Homma S; Takahara A; Namiki Y; Tsukinaga S; Mitobe J; Odahara S; Yukawa T; Matsudaira H; Nagatsuma K; Uchiyama K; Satoh K; Ito M; Komita H; Arakawa H; Ohkusa T; Gong J; Tajiri H
Clin Dev Immunol; 2011; 2011():267539. PubMed ID: 21922022
[TBL] [Abstract][Full Text] [Related]
14. Current controversies and advances in the management of pancreatic adenocarcinoma.
Zeeshan MS; Ramzan Z
World J Gastrointest Oncol; 2021 Jun; 13(6):472-494. PubMed ID: 34163568
[TBL] [Abstract][Full Text] [Related]
15. Pancreatic cancer: optimizing treatment options, new, and emerging targeted therapies.
Chiorean EG; Coveler AL
Drug Des Devel Ther; 2015; 9():3529-45. PubMed ID: 26185420
[TBL] [Abstract][Full Text] [Related]
16. Current developments, problems and solutions in the non-surgical treatment of pancreatic cancer.
Guo XZ; Cui ZM; Liu X
World J Gastrointest Oncol; 2013 Feb; 5(2):20-8. PubMed ID: 23556053
[TBL] [Abstract][Full Text] [Related]
17. Advanced Pancreatic Neuroendocrine Neoplasms: Which Systemic Treatment Should I Start With?
Rodriguez-Freixinos V; Thawer A; Capdevila J; Ferone D; Singh S
Curr Oncol Rep; 2021 May; 23(7):80. PubMed ID: 33937962
[TBL] [Abstract][Full Text] [Related]
18. Overview of resistance to systemic therapy in patients with breast cancer.
Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
[TBL] [Abstract][Full Text] [Related]
19. Treatment of pancreatic cancer: challenge of the facts.
Beger HG; Rau B; Gansauge F; Poch B; Link KH
World J Surg; 2003 Oct; 27(10):1075-84. PubMed ID: 12925907
[TBL] [Abstract][Full Text] [Related]
20. Systemic treatment of pancreatic cancer.
Van Cutsem E; Aerts R; Haustermans K; Topal B; Van Steenbergen W; Verslype C
Eur J Gastroenterol Hepatol; 2004 Mar; 16(3):265-74. PubMed ID: 15195889
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
